Crispin Davies, MD
Cardiovascular Disease · Portland, ORNPI 1982610481
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,250 of the $6,380 with a category attached, or 82.3%. Abbott accounts for 84.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $5,250 and has fallen 93.3% since, to $352 in 2025.
Across 21 payments — averaging $303.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Abiomed$519
- Medtronic$339
- Boston Scientific$70
- Shockwave Medical, Inc$19
- Teleflex LLC$17
What the payments were for
- Consulting fees$5,25082%
- Food & beverage$1,13018%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 5 | $5,417 |
| Abiomed | 7 | $519 |
| Medtronic(2 entities) | 6 | $339 |
| Boston Scientific | 1 | $70 |
| Shockwave Medical, Inc | 1 | $19 |
| Teleflex LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DRAGONFLY OPSTAR$5,250
- Impella$371
- Diamondback Peripheral$167
- SYMPLICITY G3$135
How this compares
$6,380 in reported general payments places this provider in the 80th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $53,570 |
| XareltoRivaroxaban | 17 | $16,252 |
| Repatha SureclickEvolocumab | 11 | $6,835 |
| Metoprolol Succinate | 77 | $1,372 |
| Atorvastatin Calcium | 92 | $1,034 |
| ClopidogrelClopidogrel Bisulfate | 76 | $777 |
| Ezetimibe | 55 | $704 |
| Ranolazine ErRanolazine | 15 | $655 |
| Rosuvastatin Calcium | 51 | $608 |
| Losartan Potassium | 35 | $560 |
| Carvedilol | 30 | $471 |
| Lisinopril | 44 | $410 |
| Nitroglycerin | 32 | $330 |
| Spironolactone | 22 | $228 |
| Potassium Chloride | 12 | $214 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Portland
- Firas ZahrPortland$810K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
- Stephen HeitnerPortland$105K
- Abhushan PoudyalPortland$54K
- Douglas DawleyPortland$45K
- Kishor KhanalPortland$39K
- Jeffrey MarbachPortland$19K
- Laith AlkukhunPortland$16K
- Tyler GluckmanPortland$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.